查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2138161

旅行者腹瀉（TD）：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2026-2036年

Global Traveler's Diarrhea (TD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2026 To 2036
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 156 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國TD市場預計將從2026年的3,500萬美元成長到2036年的6,500萬美元。
  • 以下因素正在推動市場成長：
  • 國際旅行增加和對疾病的認知提高
  • 對有效抗感染和預防療法的需求日益成長
  • 未來的成長取決於在預防和治療抗藥性或性行為感染方面的改進。

全球旅行者腹瀉市場展望及預測

旅行者腹瀉概述

旅行者腹瀉（TD）是一種急性感染性胃腸道症候群，由大腸桿菌、曲狀桿菌志賀桿菌、沙門氏菌、諾羅病毒和寄生蟲等腸道病原體引起。症狀輕則稀便，重則伴隨腹痛、發燒、嘔吐和脫水，持續性症狀可導致感染後併發症。治療重點在於口服補液和控制症狀，抗生素主要用於中重度病例。阿奇黴素推薦用於重症病例和伴有痢疾樣症狀的患者，而Rifaximin或利福黴素SV可用於某些非侵襲性細菌感染疾病。由於副作用和抗生素抗藥性的風險，通常不建議常規使用抗生素預防。研發趨勢正轉向病原體特異性預防和腸道菌叢保護策略，包括針對腸道病原體的口服疫苗。在預防、降低抗藥性和為高風險旅客提供便利保護方面，仍有很大的發展機會。

主要亮點

  • 據預測，德國確診的旅客腹瀉 (TD) 病例數將從 2026 年的 3,265,903 例增加到 2036 年的 4,303,734 例。
  • TD 是一種常見的胃腸道感染疾病，由旅行途中食用受污染的食物或水引起。
  • 疾病負擔受旅行期間的接觸情況、衛生條件和當地感染風險的影響。
  • 有效的預防和治療方法仍然至關重要，特別是對於抗藥性感染疾病。

市場定義：

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

目標國家：30個國家

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並正在接受藥物治療的患者族群。
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 目前主要療法－概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
  • 值得關注的早期管道

第6章：未滿足的需求與TPP分析

  • 新興療法的關鍵未滿足需求和未來成就前景
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Global Traveler's Diarrhea Market Outlook and Forecast

Thelansis's "Global Traveler's Diarrhea (TD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2026 To 2036" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Traveler's Diarrhea treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Traveler's Diarrhea Overview

Traveler's diarrhea (TD) is an acute infectious GI syndrome caused by enteric pathogens including Escherichia coli, Campylobacter, Shigella, Salmonella, norovirus, and parasites. Symptoms range from mild loose stools to severe diarrhea with abdominal pain, fever, vomiting, and dehydration; persistent cases may cause post-infectious symptoms. Management centers on oral rehydration and symptom control, with antibiotics mainly reserved for moderate or severe illness. Azithromycin is preferred for severe or dysenteric illness, while rifaximin and rifamycin SV are options for selected noninvasive bacterial infections. Routine antibiotic prophylaxis is generally discouraged because of adverse effects and antimicrobial-resistance risks. Development is shifting toward pathogen-specific prevention and microbiome-sparing strategies, including oral vaccines targeting enteric pathogens. Key opportunities remain in prevention, resistance reduction, and convenient protection for high-risk travelers.

Key Highlights

  • In Germany, diagnosed Traveler's Diarrhea (TD) cases are projected to increase from 3,265,903 in 2026 to 4,303,734 by 2036.
  • TD is a common gastrointestinal infection associated with contaminated food and water during travel.
  • Disease burden is influenced by travel exposure, sanitation, and regional infection risks.
  • Unmet need remains for effective prevention and treatment, particularly for drug-resistant infections.

Market Overview

  • The France TD market is projected to grow from $35M in 2026 to $65M by 2036.
  • Market growth is driven by:
  • Rising international travel and disease awareness
  • Increasing need for effective anti-infective and preventive therapies
  • Future growth will depend on improved prevention and treatments for resistant or persistent infections.

Market Definition:

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

30 countries covered:

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)